- cafead   Aug 11, 2022 at 12:22: PM
via Gamida Cell has dosed the first subject in the Phase I/II clinical trial of natural killer (NK) cell therapy candidate GDA-201 to treat patients with follicular and diffuse large B cell lymphomas (FL and DLBCL).
article source
article source